The goal of this study is to determine whether a medicine called tirzepatide, also calledZepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us tomeasure the effect of the treatment by having half of the participants take themedication and half take a placebo that has no medication. Participants will take themedication (or placebo) they are given and complete study surveys for 12 months. All ofthe study tasks are done remotely from the comfort of a participants home.
Not Provided
Drug: Tirzepatide
The treatment group will receive the study medication (tirzepatide) for a 12 month period
starting with a 2.5mg dose once a week.
Drug: Placebo
Participants in the control group will receive a placebo instead of active study
medication for a 12 month period.
Inclusion Criteria:
- 18 years of age or older Living in the United States Able to read and understand
English or Spanish Willing and able to participate in study interventions and
activities, including;
- Access to an internet connected device
- Informed Consent
- Surveys
- Medication schedule
- Adverse Event reporting
- Weight reporting
- Use of wearable activity tracker
- Completing at home blood collections, if selected Meets the NASEM definition of Long
COVID: an infection-associated chronic condition that occurs after SARS-CoV-2
infection and is present for at least 3 months as a continuous, relapsing and
remitting, or progressive disease state that affects one or more organ systems 16.
Ability to verify identity Ability to verify diagnosis Agree to notify the study team if
you start any other Long COVID treatments while enrolled in the study.
Complete the Fatigue Severity Scale with a minimum score of 36
Exclusion Criteria:
- Certain vulnerable populations (prisoners, children, fetuses, and institutionalized
individuals)
- Women who are pregnant, excluded due to unknown risks to a fetus
- Personal or family history of medullary thyroid carcinoma
- History of severe gastrointestinal disease
- Diagnosis of gastroparesis
- Worsening or chronic renal failure
- History of pancreatitis
- Multiple Endocrine Neoplasia syndrome type 2
- Known serious hypersensitivity to tirzepatide
- Already taking tirzepatide or another GLP-1 agonist
- Medication contraindications to tirzepatide
- History of suicidal attempts and/or active suicidal ideation
- Underweight (BMI under 18.5)
- Planning to undergo elective surgery or procedures requiring general anesthesia or
deep sedation in the next 12 months
- Symptoms of fatigue and/or brain fog that predated infection with COVID-19
Scripps Research
La Jolla 5363943, California 5332921, United States
Investigator: Julia Moore Vogel, PhD
Contact: 858-784-9519
longcovid-t@scripps.edu
Andrea Goosen
858-784-5219
agoosen@scripps.edu
Romina Foster-Bonds
858-784-5219
rfoster@scripps.edu
Julia Moore Vogel, Principal Investigator
Scripps Translational Research Institute